New combo therapy targets tough brain tumors
NCT ID NCT03050736
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tested a drug called VAL-083 combined with standard radiation in 29 people with newly diagnosed glioblastoma, a fast-growing brain cancer. The study focused on patients whose tumors have a specific genetic marker (unmethylated MGMT) that makes them resistant to standard chemotherapy. The goal was to find the safest dose and see if the combination can shrink tumors or slow their growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VAL-083 (dianhydrogalactitol)
What this could lead to
If successful, this could offer a new treatment option for glioblastoma patients whose tumors do not respond to standard chemotherapy.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply to all patients. The drug may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, 510060, China